CDKN2A Gene Expression as a Potential Aging Biomarker in Dogs

Sára Sándor* 1, Kitti Tátrai 1,2, Kálmán Czeibert 1, Balázs Egyed 2 and Enikő Kubinyi 1

1 Department of Ethology, Senior Family Dog Project, ELTE Eötvös Loránd University, Budapest, Hungary, 2 Department of Genetics, ELTE Eötvös Loránd University, Budapest, Hungary

Describing evolutionary conserved physiological or molecular patterns, which can reliably mark the age of both model organisms and humans or predict the onset of age-related pathologies has become a priority in aging research. The age-related gene-expression changes of the Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) gene have been well-documented in humans and rodents. However, data is lacking from other relevant species, including dogs. Therefore, we quantified the CDKN2A mRNA abundance in dogs of different ages, in four tissue types: the frontal cortex of the brain, temporal muscle, skin, and blood. We found a significant, positive correlation between CDKN2A relative expression values and age in the brain, muscle, and blood; however, no correlation was detected in the skin. The strongest correlation was detected in the brain tissue (CDKN2A/GAPDH: r = 0.757, p < 0.001), similarly to human findings, while the muscle and blood showed weaker, but significant correlation. Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the validation and optimization will require further, more focused research. Our current results also clearly demonstrate that the role of CDKN2A in aging is conserved in dogs, regarding both tissue specificity and a pivotal role of CDKN2A in brain aging.

Keywords: CDKN2A, dog, aging, biomarker, gene expression, blood

INTRODUCTION

Dogs have received growing attention as model animals of human aging and neurodegeneration because they are prone to developing similar age-related pathologies within a much shorter lifetime, and they are exposed to the same environmental and lifestyle stressors present in the modern human environment (1–4). Understanding how they age could also bestow benefits on the animals and their owners through advancing veterinary diagnostics.

Currently, in humans, the lack of universally applicable and highly reliable biomarkers, which can predict mortality and the onset of age-related pathologies is a major obstacle in the way of translational research goals and developing effective preventive approaches and therapies (5).

So far, several physiological and molecular parameters have been proposed as predictors of biological age and disease status in humans. However, most of these have limitations regarding clinical applicability and range of validity. For example, traditional clinical biomarkers, like blood pressure or cholesterol levels, which could predict mortality in younger cohorts, often lose their predictive capacity in older people (6, 7).

Epigenetic markers are promising candidates for developing a reliable and universal system predicting the course of aging (8, 9). Importantly, epigenetic signatures of certain genomic regions are conserved between humans, rodents, and dogs (10, 11) and an epigenome-based
age-determination system has been recently developed for Labrador retriever dogs (12). Nevertheless, defining molecular markers beyond epigenetic patterns or telomere shortening has been recommended by several authors to increase the precision of predictions and to allow the monitoring of specific diseases (13, 14). Recently, for example, a panel of blood-borne markers was proposed as appropriate for geroscience research in humans (15).

In dogs, the neuronal cytoskeletal protein neurofilament light chain (NFL) has recently been validated as a marker of age-related neurodegeneration, which could augment translational research as well (16). Gene expression based markers in general, however, may show fundamental differences between species as was reported by Hudgins et al. in 2018, when they compared the expression patterns in different tissues of mice and humans. In contrast, the expression of the p16(INK4A) transcript, together with p14(ARF) (p19 in mice), both encoded by the Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) gene, have been reported to show a similar pattern of increased expression with aging in humans and rodents (17–19). The expression of the CDKN2A gene - which plays an important role in cell-cycle inhibition and is a tumor suppressor (20), has been reported to be an evolutionarily conserved regulator of cellular senescence (21). Its potential as a biomarker to predict biological age was proposed to even surpass telomeres in humans (22, 23). Also, it was shown to predict renal allograft function with higher accuracy than telomere length and chronological age (24).

Based on these results, CDKN2A expression has been proposed as a highly promising molecular biomarker of human aging (25–27). Furthermore, CDKN2A levels in blood were reported to be indicative of accelerated cellular aging caused by various infections or type 2 diabetes (28–30). Importantly, similar findings were reported in rodents [reviewed by Sorrentino et al. (31) in 2014], supporting the conserved nature of CDKN2A expression as a marker of cellular senescence. However, CDKN2A’s role in aging has not yet been investigated in other mammalian clades. Assessing the applicability of CDKN2A as an aging biomarker in dogs may further support reliable age-determination in translational research with this species (32). To this end, we investigated the mRNA expression of the canine CDKN2A gene in the brain (frontal cortex), muscle (m. temporalis), and skin (head area), obtained from pet dogs of various breeds within the frames of study 1, to test whether CDKN2A shows a similar tissue-expression pattern in this species as has been reported in humans and rodents. Due to methodological limitations, blood samples could not be analyzed from the same individuals (see details in Materials and Methods). Therefore, a population consisting of border collie dogs, which were available as participants of an independent study, were included in study 2 to assess the correlation between CDKN2A expression and age in blood.

**METHODS**

**Ethics Statement**

The biological sample collection conducted in this study complied with national [Hungarian law (31998. évi XXVIII. Törvény” 3. §/9.—The Animal Protection Act)] and EU legislation, with the recommendations in the International Society for Applied Ethology guidelines for the use of animals in research, as well as institutional guidelines. The Hungarian “Animal Experiments Scientific and Ethical Committee” approved the experimental procedures under the number: PEI/001/1457-4/2015. The owners provided written consent for their dogs’ participation.

**Subjects**

**Study 1**

Twenty-six dogs (age ranged from 1 to 18 years old) were included in this study. The sex, breed, and body weight of the animals are presented in Table 1. The relative ages of the animals were calculated as chronological age * 100/expected lifespan of the breed (33). In the case of mixed-breed dogs, the expected lifespan was calculated by the formula postulated by Greer et al. (34) [version with cm and kg instead of inch and pound were provided by Szabó et al. (35): 13.62 + height_in_cm * 0.03 - weight_in_kg * 0.12].

**Study 2**

Two whole blood samples were taken from 15 border collie dogs (their age ranged from 9 months to 15 years old, Table 2). In this study, no correction for relative age was necessary due to the homogenous breed composition of the sample.

**Donation and Sampling**

**Study 1**

The animals used in study 1 were donated to the Hungarian Canine Brain and Tissue Bank (CBTB) by their owners, who had previously been informed about the donation possibility through various forums, e.g., social media [(36), submitted]. The animals were euthanized by their veterinarian only for justified medical reasons. Both the owner and the veterinarian gave written consent for the euthanasia and the donation and confirmed that the animal had not had infectious zoonosis prior to euthanasia and had been vaccinated against rabies. After the dogs were euthanized, the bodies were immediately transported to the facility of the CBTB, and dissection was performed by a veterinary anatomist (KC) to obtain tissues within a pre-set 4 h post-mortem limit. After removal from the skull, whole brains were rinsed in phosphate-buffered saline for 5 min, and then cortical samples were removed bilaterally from the area of the frontal lobe. Muscle tissue pieces were obtained from the medial aspect of the musculus temporalis and skin was harvested from the head of the animals. Each tissue piece was cut to be 80–120 mg in mass and was immersed in 1 ml RNAlater. The samples were then incubated at 4°C overnight to enable total percolation of the RNAlater. The next day, the supernatant was removed, and the tissues were frozen at −80 or −20°C for long-term or short-term storage, respectively. Blood was not collected for molecular investigations during standard post-mortem sampling protocols as it was previously found to be highly hemolized due to the application of T-61 as euthanasia agent (37).
**TABLE 1** | Dogs included in study 1.

| Breed                      | Sex   | Body weight (kg) | Body height at withers (cm) | Chronological age (months) | Expected lifespan (months) | Relative age (% of expected) |
|----------------------------|-------|------------------|-----------------------------|---------------------------|---------------------------|------------------------------|
| Border collie              | Female| 10.7             | 45                          | 9                         | 147                       | 8                            |
| Boxer                      | Female| 20.4             | 61                          | 14                        | 123                       | 9                            |
| Chihuahua                  | Female| 3.6              | 25                          | 24                        | 149                       | 16                           |
| Beagle                     | Female| 7.5              | 38                          | 48                        | 152                       | 31                           |
| Beagle                     | Female| 9.7              | 38                          | 48                        | 152                       | 31                           |
| Beagle                     | Female| 10.6             | 39                          | 48                        | 152                       | 31                           |
| Beagle                     | Female| 7.7              | 36                          | 48                        | 152                       | 31                           |
| German shepherd dog        | Female| 20.2             | 70                          | 49                        | 120                       | 40                           |
| Gordon setter              | Male   | 37.4             | 69                          | 46                        | 133                       | 36                           |
| Mongrel                    | Male   | 15.5             | 51                          | 45                        | 158                       | 28                           |
| Yorkshire terrier          | Female| 2.1              | 22                          | 72                        | 152                       | 47                           |
| Doberman                   | Female| 25.1             | 63                          | 96                        | 126                       | 86                           |
| Golden retriever           | Female| 25.8             | 58                          | 84                        | 147                       | 57                           |
| Mongrel                    | Male   | 17.9             | 45                          | 108                       | 153                       | 70                           |
| Vizsla                     | Male   | 24.5             | 60                          | 120                       | 162                       | 74                           |
| Border collie              | Female| 20.4             | 51                          | 142                       | 147                       | 97                           |
| Labrador retriever         | Male   | 36.1             | 57                          | 153                       | 147                       | 106                          |
| Border collie              | Female| 13.2             | 49                          | 167                       | 147                       | 114                          |
| Labrador retriever         | Male   | 28.4             | 60                          | 168                       | 147                       | 114                          |
| Labrador retriever         | Female| 25.4             | 56                          | 161                       | 146                       | 110                          |
| Labrador retriever         | Male   | 26.9             | 59                          | 163                       | 147                       | 114                          |
| Dachshund                  | Female| 5                | 28                          | 204                       | 152                       | 134                          |
| Golden retriever           | Female| 22               | 56                          | 197                       | 147                       | 138                          |
| Mongrel                    | Female| 7.4              | 45                          | 204                       | 168                       | 121                          |
| Small Münsterlander        | Female| 12.7             | 47                          | 201                       | 150                       | 136                          |
| Mongrel                    | Male   | 8.6              | 35                          | 204                       | 163                       | 125                          |

**Study 2**

Blood was collected from living companion dogs. The date of birth and the breed of the dogs were confirmed based on the dog’s pedigree and/or dog passports verified by their veterinarians. Based on the owners’ reports, all dogs were healthy and did not take any medication at least 2 weeks before the sampling. One milliliter blood was collected into an EDTA tube and immediately sent to a veterinarian diagnostic laboratory to verify the animals’ health status. The blood collection was performed by an experienced veterinarian. Additional 3 ml blood samples were collected into DNA/RNA Blood Collection Tubes (Zymo Research), and were mixed gently, according to the manufacturer’s protocol. The blood-filled tubes were stored in a −20°C freezer until further processing.

**RNA Isolation**

**Study 1**

Total cellular RNA was isolated from the frontal cortex, temporal muscle, and skin tissue samples stored frozen in RNAlater using TRIzol (Thermo Fisher) and following the manufacturer’s protocol. Prior to immersing the tissue pieces in TRIzol, each piece was rinsed in 1 ml of sterile PBS in a new tube and centrifuged for 5 min on 500 g. TRIzol was added to the samples after removal of the PBS. Homogenization of the tissue pieces was carried out by an Ultra-Turrax homogenizer (Ika) under a fume hood to prevent inhalation of TRIzol. After homogenization, the isolation process took place following standard procedures of TRIzol based RNA isolation.

**TABLE 2** | Border collie dogs included in study 2.

| Age (months) | Sex    |
|-------------|--------|
| 9           | Female |
| 15          | Male   |
| 17          | Female |
| 17          | Female |
| 41          | Female |
| 58          | Female |
| 48          | Male   |
| 121         | Female |
| 120         | Female |
| 125         | Male   |
| 129         | Male   |
| 138         | Female |
| 144         | Male   |
| 171         | Male   |
| 183         | Female |
RNA was isolated from blood samples using the Quick-DNA/RNA Blood Tube Kit (Zymo Research) following the manufacturer’s protocol. The integrity of all isolates was checked by agarose gel electrophoresis. Purity and concentrations were measured by a NanoDrop 1000 device (Thermo Fisher). RNA samples were stored in a −80°C freezer.

### cdNA Synthesis and Real-Time PCR

Thousand nanogram of each total RNA was reverse transcribed into cdNA using the Maxima RevertAid cdNA Synthesis Kit (Thermo Fisher). The reactions were performed following the manufacturer’s protocol, using random hexamer primers. Prior to downstream applications, the cdNA samples were diluted 10-fold by nuclease-free water and kept at −20°C. For long-term storage, the cdNA samples were placed at −80°C.

Quantitative Real-Time PCR reactions were performed in 10 μl total volume with 3 technical parallels on a LightCycler 96 Instrument (Roche) using the PowerUp SYBRGreen Master Mix (Thermo Fisher) and specifically designed primers for canine CDKN2A, Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH), Ribosomal Protein Lateral Stalk Subunit P0 (RPLP0) and Hydroxymethylbilane Synthase (HMBS). HMBS was previously reported to be a highly stable transcript across different canine tissues (38, 39), while GAPDH was reported to be highly expressed both in brain and muscle tissue in humans (40, 41). Therefore, these two genes seemed appropriate to cover the expected range of expression in the solid tissues. RPLP0 was chosen instead of GAPDH to test blood, as suggested by previous human studies (42). Primers sequences used to detect each transcript were the following: CDKN2A forward: 5′- GAGGGC TTCTGGGACACG, reverse: 5′- TCAATCTCTGAAGTGCCGG GCT; GAPDH forward: 5′-GAGATCCCGCCAACTCAAT GG, reverse: 5′-TACTTCTCATGGTTCACGCCCAT; HMBS forward: 5′-ACTCTCTGAGGACCTGC, reverse: 5′-CTCTTC TCTGGCAAGGTTC; RPLP0 forward: 5′- TTCTCGCTTCTTT GAGGTTG, reverse: 5′- CAGGACCCCGTTGTATCCAT.

### Statistical Analysis

Relative gene expression of CDKN2A was determined using the delta Ct method, by applying GAPDH and HMBS as endogenous controls in hard tissues and RPLP0 together with HMBS in blood. Relative age and frontal cortex CDKN2A relative expression values were not normally distributed, therefore we used Spearman correlation for investigating the relationship between the variables in SPSS v25. Receiver operating characteristic (ROC) curve analysis was also performed by this software. In the first study, age categories (“young” and “old”) were divided following human conventions: the threshold of being old is often set at 65 years of age in modern societies and the expected lifespan linked to these populations is around 82 years (43). Therefore, dogs were considered “old” when their relate age were above 80% of the expected lifespan.

### RESULTS

#### CDKN2A Expression in Dog Tissues

CDKN2A mRNA was detectable in all tissue types included in this study: brain (frontal cortex), temporal muscle, skin, and blood. In hard tissues (study 1), the relative expression values of CDKN2A were highest in the frontal cortex samples and lowest in the skin samples, while muscle showed a mid-level expression in comparison to the same endogenous control genes (GAPDH and HMBS). Blood samples (study 2) showed an intermediate expression level between the cortical and skin samples based on the CDKN2A / HMBS ratio.

#### The Correlations Between CDKN2A Expression and the Animals’ Age Were Tissue-Specific

**Study 1**

We found a positive correlation between the relative age of the animals (see Materials and Methods) and CDKN2A relative expression in the frontal cortex and muscle tissue (frontal cortex CDKN2A/GAPDH: \( r = 0.757, p < 0.001 \); frontal cortex CDKN2A/HMBS: \( r = 0.627, p = 0.001 \); muscle CDKN2A/GAPDH: \( r = 0.456, p = 0.022 \); muscle CDKN2A/HMBS: \( r = 0.435, p = 0.030 \); Table 3). However, no significant correlation was detected in the skin samples.

Regarding data from the muscle samples, one 4-year-old dog was an extreme outlier showing a relative expression level ~5 times higher than the average of the other individuals. When the outlier was excluded from the analysis, the level of the correlation between age and CDKN2A relative expression increased in the muscle dataset (muscle CDKN2A/GAPDH: \( r = 0.544, p < 0.001 \), muscle CDKN2A/HMBS: \( r = 0.515, p = 0.010 \)), yet still remained much weaker than in the brain tissue of the same animals.

CDKN2A relative expression values correlated between the frontal cortex and muscle, however the expression in skin did not show such correlations with the other tissue types (Table 3). Neither of the other known variables (weight, height, or sex of the animals) affected the CDKN2A relative expression values.

ROC curve analysis was applied to test the capacity of CDKN2A relative expression to predict the relative age of the animals in the three tissue types. AUC values exceeded 0.9 in the brain tissue independently of the used endogenous control gene (CDKN2A/GAPDH AUC = 0.976; CDKN2A/HMBS AUC = 0.921, \( p < 0.01 \)). Similarly to the correlation results, AUC was smaller, but still significant in the muscle (CDKN2A/GAPDH AUC = 0.853; CDKN2A/HMBS AUC = 0.846, \( p < 0.01 \)) and were around the 0.5 random level in the skin tissue.

**Study 2**

In the second study, in which blood samples obtained from border collies were analyzed, the relative expression values of CDKN2A also showed a significant, positive correlation with the age of the animals (CDKN2A/RPLP0: \( r = 0.592, p < 0.05 \); CDKN2A/HMBS: \( r = 0.539, p < 0.05 \)).

ROC curve analysis, however, barely exceeded the 0.5 level (0.695 and 0.781, for HMBS and RPLP0 controls, respectively) in the blood and significance did not reach the \( p < 0.05 \) values.


**TABLE 3** | Spearman’s correlations between relative age and CDKN2A relative expression values.

|                      | Relative age | Frontal cortex/GAPDH | Frontal cortex/HMBS | Skin/GAPDH | Skin/HMBS | Muscle/GAPDH | Muscle/HMBS |
|----------------------|-------------|----------------------|---------------------|------------|-----------|--------------|-------------|
| Relative age         | Correlation | 1.000                | 0.757**             | 0.627**    | 0.257     | 0.148        | 0.456*      | 0.435*      |
|                      | Coefficient | p (2-tailed)         | 0.000               | 0.001      | 0.236     | 0.499        | 0.022       | 0.030       |
|                      |             | N                    | 26                  | 26         | 26        | 23           | 25          | 25          |
| Frontal cortex/GAPDH | Correlation | 0.757**              | 1.000               | 0.902**    | 0.135     | −0.164       | 0.559**     | 0.533**     |
|                      | Coefficient | p (2-tailed)         | 0.000               | 0.000      | 0.538     | 0.455        | 0.004       | 0.006       |
|                      |             | N                    | 26                  | 26         | 26        | 23           | 25          | 25          |
| Frontal cortex/HMBS | Correlation | 0.627**              | 0.902**             | 1.000      | 0.073     | −0.323       | 0.624**     | 0.627**     |
|                      | Coefficient | p (2-tailed)         | 0.001               | 0.000      | 0.740     | 0.133        | 0.001       | 0.001       |
|                      |             | N                    | 26                  | 26         | 26        | 23           | 25          | 25          |
| Skin/GAPDH           | Correlation | 0.257                | 0.135               | 0.073      | 1.000     | 0.398        | 0.074       | 0.048       |
|                      | Coefficient | p (2-tailed)         | 0.236               | 0.538      | 0.740     | 0.060        | 0.745       | 0.832       |
|                      |             | N                    | 23                  | 23         | 23        | 23           | 25          | 25          |
| Skin/HMBS            | Correlation | 0.148                | −0.164              | −0.323     | 0.398     | 1.000        | −0.326      | −0.373      |
|                      | Coefficient | p (2-tailed)         | 0.499               | 0.455      | 0.133     | 0.060        | 0.139       | 0.087       |
|                      |             | N                    | 23                  | 23         | 23        | 23           | 22          | 22          |
| Muscle/GAPDH         | Correlation | 0.456*               | 0.559**             | 0.624**    | 0.074     | −0.326       | 1.000       | 0.981**     |
|                      | Coefficient | p (2-tailed)         | 0.022               | 0.004      | 0.001    | 0.745        | 0.139       | 0.000       |
|                      |             | N                    | 25                  | 25         | 25        | 22           | 25          | 25          |
| Muscle/HMBS          | Correlation | 0.435*               | 0.533**             | 0.627**    | 0.048     | −0.373       | 0.981**     | 1.000       |
|                      | Coefficient | p (2-tailed)         | 0.030               | 0.006      | 0.001    | 0.832        | 0.087       | 0.000       |
|                      |             | N                    | 25*                 | 25         | 25        | 22           | 25          | 25          |

*Indicates significant correlations (*p < 0.05, **p < 0.01, ***p < 0.001).

**DISCUSSION**

We showed that CDKN2A expression positively correlated with chronological age in the frontal cortex and temporal muscle tissues, but not in skin tissues of dogs belonging to various breeds. These findings were in accordance with previous reports from humans, where both brain and muscle were found to have highly elevated levels of CDKN2A in older people, while an elevation in the skin was moderate and did not reach significance (44, 45). In our study, one outlier among the muscle samples belonged to a dog which had a medical history of epileptic seizures and was euthanized because of a grand mal seizure. The muscle tissue of this dog showed a greatly elevated relative expression of CDKN2A. Literature is scarce regarding the effects of seizures on muscle damage (46) and how this would affect the expression of CDKN2A. One study has shown that acute muscle damage leads to an increase in the number of senescent cells with elevated CDKN2A expression at least in certain muscle-associated cell types (47). In another study, an elevation in the expression of the p16INK4A transcript, a product of the CDKN2A gene, was reported in acute kidney injury in young mice (48). Therefore, it is tempting to hypothesize that generalized muscle convulsions could have caused the dramatically elevated CDKN2A levels in the muscle tissue of the outlier animal, as no similar elevation was detected in the brain or skin. This hypothesis could also pave the way for investigating CDKN2A as a marker of tissue damage. It has recently been suggested by single-cell transcriptomics that the robust, age-related elevation in CDKN2A levels may be caused by the increasing ratio of senescent cells with higher damage/mutational load and not by an intrinsic aging program that generally upregulates its expression in all cells (49). The increased individual variability seen in muscle and skin may have contributed to the decrease/lack of correlation between age and CDKN2A gene expression in these tissues. As another possible confounder, the expression stability of the applied housekeeping genes should also be considered. Although the choice of GAPDH and HMBS for solid tissues was based on previous literature data indicating these as generally stable transcripts, no previous data was available regarding the possible age-related changes of these genes’ expression in dog tissues. In the case of HMBS, we detected a marginal, negative correlation between expression and dogs’ age in the muscle tissue ($r = −0.417$, $p < 0.05$), indicating that this gene was not an optimal control to assess age-related gene expression changes. This finding underlines why it is advisable to include more than one control gene in an RT-qPCR experiment (50).
Importantly, the tissue-specific correlations we detected in our dog population were concordant with previous findings reported from humans (44, 51). Although none of these studies compared frontal cortex, skin and muscle in a similar setting as reported herein, pairwise comparisons between muscle and skin (44) or brain and skin (52) showed similar patterns, reporting no significant changes in CDKN2A expression in skin, only in the other tissues. Indications for similar tissue specificity were also reported in both mice and humans, with extreme outliers occurring in several datasets (53, 54). This phenomenon was also seen in humans when the same tissues from different body parts (e.g., skin from sun-exposed vs. protected areas) were compared (54). Altogether, this suggests that age-related gene expression changes can vary widely between samples, depending on species, genetic background, tissue type, and environmental factors. In this regard, our findings could be an important addition to CDKN2A biomarker research, because we used a mixed population of dogs in study 1, including several breeds and mongrels in the analysis. Therefore, we demonstrated that CDKN2A could be a powerful tool for following age-related changes in certain tissues of dogs, independently of individual genetic background.

In humans the most important feature of CDKN2A as a biomarker of aging is its availability in the blood and the validated correlations between its blood expression levels and age/cellular damage or senescence in other tissues (26, 28–30). In order to gain insight into the expression changes of CDKN2A in the blood of dogs, we investigated a second cohort of animals. Due to considerations related to a different study, this cohort included only animals from the same breed (border collie). Therefore, the results of study 2 are not indicative of the expression variance of CDKN2A in a multi-breed dog population. Comparisons between different breeds will be required, to test if blood sample data for CDKN2A expression behaves similarly stable across animals of different genetic backgrounds. Also, the correlation between CDKN2A expression and age was weaker in the blood than seen in the brain tissue in study 1, and the ROC curve analysis did not indicate a good predictive capacity in this sample population. Importantly, one of the main reasons for this could be the large variability seen in individual expression values in the blood, coupled with the limited sample number of 5 old vs. 5 young animals. Human studies suggested that reliable gene expression detection might be challenging from whole blood samples, which are a mixture of different cell types (55). Therefore, further optimization of the method used to analyze blood, including the separation of white blood cells (“buffy coat”), may yield more consistent results regarding the link between CDKN2A levels and biological age. In humans, T lymphocytes were reported to show the most robust CKDN2A expression change with aging (26).

A main limitation of our study is the lack of solid tissue and blood samples from the same animals. The reason was methodological: all animals were euthanized by chemical agents, which causes severe hemolysis (37, 56). We found no data about the comparability of hemolyzed blood samples with normal samples regarding mRNA gene expression analyses, while in regard to miRNA-s it was reported that hemolysis could modify the results (57). Therefore, the use of hemolyzed blood samples was not considered appropriate for our study aims. Another major limitation is the limited size and non-continuous composition of the sample population in study 2. The animals participating in this study were recruited for other ongoing study goals, where a young-old age composition was required. For practical reasons – e.g., the limited mobility of both owners and personnel due to the COVID outbreak -, the number of involved animals could not be increased to include dogs with intermediate ages.

Altogether, our findings about the robust age-related increase in CDKN2A mRNA levels in some dog tissues propose an evolutionary conserved aging pathway, which could be applied as a reliable aging marker in dogs, increasing the number of currently available blood-borne biomarkers in this species (11, 12, 16, 58, 59). Previous studies in humans suggest that the number of simultaneously assessed markers could dramatically increase the efficiency of disease categorization and prediction, especially in the case of various forms of dementia (60–63). Importantly, CDKN2A has already been implicated as a regulator (64, 65) and biomarker (66) of human Alzheimer’s disease (AD), however, its exact link to disease occurrence and progression is still unclear (67).

Since dogs have been proposed as natural models of human AD (68) and live shorter lives than humans, future longitudinal studies conducted in dogs may help researchers to characterize the links between blood CKDN2A levels and age-related brain pathologies more precisely. Although the validation of blood CDKN2A level as a reliable marker of aging will require further experiments, our preliminary findings indicate that CDKN2A could be a promising predictor of biological aging, and possibly age-related pathologies in the dog.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Hungarian Animal Experiments Scientific and Ethical Committee. Written informed consent was obtained from the owners for the participation of their animals in this study.

**AUTHOR CONTRIBUTIONS**

SS designed study plan, performed laboratory work, did statistical analyses, and wrote the manuscript. KT performed laboratory work. KC provided samples for the laboratory work and contributed to writing. BE provided laboratory equipment and materials and contributed to writing. EK contributed to writing.
did statistical analyses, and provided funding. All authors contributed to the article and approved the submitted version.

**FUNDING**

This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 680040) and the Hungarian Brain Research Program 2017-1.2.1-NKP-2017-00022.

**ACKNOWLEDGMENTS**

We are grateful to Ivaylo Iotchev and Lisa Wallis for providing a comprehensive grammar check and for the useful suggestions and ideas, which helped to finalize our manuscript.
35. Szabó D, Gee NR, MiklósÁ. Natural or pathological? Discrepancies in the study of behavioral and cognitive signs in aging family dogs. *J Vet Behav.* (2016) 11:68–96. doi: 10.1016/j.jvetbehav.2015.08.003

36. Sándor S, Cezeibert K, Salamon A, Kubinyi E. Man’s best friend in life and death: scientific perspectives and challenges of dog brain banking (unpublished manuscript).

37. Prien T, Traber DL, Linares HA, Davenport SL. Haemolysis and artificial lung damage induced by an euthanasia agent. *Lab Anim.* (1988) 22:170–2. doi: 10.1258/002377888780864420

38. Park S-J, Huh J-W, Kim Y-H, Lee S-R, Kim S-H, Kim S-U, et al. Specific expression of senescence biomarkers in mice. *Biochim Biophys Acta.* (2005) 1734:141–3. doi: 10.1016/j.bioch.2005.05.022

39. United Nations, Department of Economic and Social Affairs, Population Division. *World Population Ageing 2019: Highlights* (ST/ESA/SER.A/430), New York, NY, (2019).

40. Ardile KG, DeLuca DS, Segrè AV, Sullivan TJ, Young TR, Gelfand ET, et al. The genotype-tissue expression (GTEx) pilot study: multissue gene regulation in humans. *Science (80-.).* (2015) 348:648–60. doi: 10.1126/science.1262110

41. Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. *Physiol Genomics.* (2005) 21:389–95. doi: 10.1152/physiolgenomics.00025.2005

42. Dheda K, Huggett JF, Chang JS, Kim LU, Bustin SA, Johnson MA, et al. The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. *Anat Biochem.* (2005) 344:1–3. doi: 10.1016/j.ab.2005.11.077

43. Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. *Physiol Genomics.* (2005) 21:389–95. doi: 10.1152/physiolgenomics.00025.2005

44. Ardlie KG, DeLuca DS, Segrè AV, Sullivan TJ, Young TR, Gelfand ET, et al. The genotype-tissue expression (GTEx) pilot study: multissue gene regulation in humans. *Science (80-.).* (2015) 348:648–60. doi: 10.1126/science.1262110

45. Shavlakadze T, Morris M, Fang J, Wang SX, Zhu J, Zhou W, et al. Age-related gene expression signature in rats demonstrate early, late, and linear transcriptional changes from multiple tissues. *Cell Rep.* (2019) 28:3263–73.e3. doi: 10.1016/j.celrep.2019.08.043

46. Zahn JM, Poosala S, Owen AB, Ingram DK, Lastig A, Carter A, et al. AGEMAP: a gene expression database for aging in mice. *PLoS Genet.* (2007) 3:e201. doi: 10.1371/journal.pgen.0030201

47. Yang J, Huang T, Petralia F, Long Q, Zhang B, Argmann C, et al. Altered blood gene expression changes across multiple tissues in human and the link to complex diseases. *Sci Rep.* (2015) 5:1–16. doi: 10.1038/srep15145

48. Fun H, Hedeg P. The transcriptome in blood: challenges and solutions for robust expression profiling. *Carr Mol Med.* (2005) 5:3–10. doi: 10.2174/156652405315135861

49. McKeveiT TP, Nasir L, Devlin P, Argyle DJ, Telomere lengths in dogs decrease with increasing donor age. *J Nutr.* (2002) 132:1604–8S. doi: 10.1093/jn/132.6.1604S

50. Doughty MJ, Stuart D. Quantification of the hemolysis associated with use of T-61(R) as an euthanasia agent in rabbits - A comparison with Euthanyl(R). (pentobarbital sodium) and the impact on serum hexosaminidase measurement. *Can J Physiol Pharmacol.* (1995) 73:1274–80. doi: 10.1139/y95-179

51. Kirschner MB, Edelman JB, Kao SC-H, Valleye MP, van Zandwijk N, Reid G. The impact of hemolysis on cell-free microRNA biomarkers. *Front Genet.* (2013) 4:94. doi: 10.3389/fgene.2013.00094

52. Zhang YM, Ramesh N, Li CY, Huang SM, Kuo CH, et al. The expression of tissue-specific senescence biomarkers in aging dog brain. *Brain Struct Funct.* (2018) 223:1189–99. doi: 10.1007/s00429-018-1639-4

53. Fick LJ, Fick GH, Li Z, Cao E, Bao B, Heffelfinger D, et al. Telomere length correlates with life span of dog breeds. *Cell Rep.* (2012) 2:1530–6. doi: 10.1016/j.celrep.2012.11.021

54. Fransquet PD, Ryan J. The current status of blood epigenetic biomarkers for dementia. *Crit Rev Clin Lab Sci.* (2019) 56:345–57. doi: 10.1080/10408363.2019.1639129

55. Parrenti L, Paciotti S, Farotti L, Bellomo G, Sepe FN, Eusebi P, Parkinson's and Lewy body dementia CSF biomarkers. *Clin Chim Acta.* (2019) 495:318–25. doi: 10.1016/j.cca.2019.04.078

56. Züchner S, Gilbert JR, Martin ER, Leon-Guerrero CR, Xu P-T, Browning C, et al. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. *Alzheimer's Res Ther.* (2017) 9:1–15. doi: 10.1186/s13195-017-0301-7

57. Moetter LH, Donker Kaat L, Rohrer JD, van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. *Nat Rev Neurol.* (2017) 13:406–19. doi: 10.1038/nrneurol.2017.75

58. Antonell A, Lladó A, Sánchez-Valle R, Sanfeliu C, Casserras T, Ramí L, et al. Parkinson’s disease families linked to 9p21.3. *Front Aging Neurosci.* (2016) 8:279. doi: 10.3389/fnagi.2016.00279

59. Bajard L, Czaić D, Cezeibert K, Salamon A, Kubinyi E. Man’s best friend in life and death: scientific perspectives and challenges of dog brain banking (unpublished manuscript).

60. Glass D, Viñuela A, Davies MN, Ramasamy A, Parts L, Knowles D, et al. Gene expression changes with age in skin, adipose tissue, blood and brain. *Genome Biol.* (2002) 3:research0034.1. doi: 10.1186/gb-2002-3-7-research0034

61. Glass D, Viñuela A, Davies MN, Ramasamy A, Parts L, Knowles D, et al. Gene expression changes with age in skin, adipose tissue, blood and brain. *Genome Biol.* (2002) 3:research0034.1. doi: 10.1186/gb-2002-3-7-research0034

62. Yang J, Huang T, Petralia F, Long Q, Zhang B, Argmann C, et al. Altered blood gene expression changes across multiple tissues in human and the link to complex diseases. *Sci Rep.* (2015) 5:1–16. doi: 10.1038/srep15145

63. Fun H, Hedeg P. The transcriptome in blood: challenges and solutions for robust expression profiling. *Carr Mol Med.* (2005) 5:3–10. doi: 10.2174/156652405315135861

64. Doughty MJ, Stuart D. Quantification of the hemolysis associated with use of T-61(R) as an euthanasia agent in rabbits - A comparison with Euthanyl(R). (pentobarbital sodium) and the impact on serum hexosaminidase measurement. *Can J Physiol Pharmacol.* (1995) 73:1274–80. doi: 10.1139/y95-179

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2021 Sándor, Tátrai, Cezeibert, Egyed and Kubinyi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Frontiers in Veterinary Science | www.frontiersin.org 8 April 2021 | Volume 8 | Article 660435